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double-blind clinical trial investigating sacral
neuromodulation for neurogenic lower urinary
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Background: Sacral neuromodulation has become a well-established and widely accepted treatment for refractory
non-neurogenic lower urinary tract dysfunction, but its value in patients with a neurological cause is unclear.
Although there is evidence indicating that sacral neuromodulation may be effective and safe for treating
neurogenic lower urinary tract dysfunction, the number of investigated patients is low and there is a lack of
randomized controlled trials.
Methods and design: This study is a prospective, randomized, placebo-controlled, double-blind multicenter trial
including 4 sacral neuromodulation referral centers in Switzerland. Patients with refractory neurogenic lower urinary
tract dysfunction are enrolled. After minimally invasive bilateral tined lead placement into the sacral foramina S3
and/or S4, patients undergo prolonged sacral neuromodulation testing for 3–6 weeks. In case of successful (defined
as improvement of at least 50% in key bladder diary variables (i.e. number of voids and/or number of leakages, post
void residual) compared to baseline values) prolonged sacral neuromodulation testing, the neuromodulator is
implanted in the upper buttock. After a 2 months post-implantation phase when the neuromodulator is turned ON
to optimize the effectiveness of neuromodulation using sub-sensory threshold stimulation, the patients are
randomized in a 1:1 allocation in sacral neuromodulation ON or OFF. At the end of the 2 months double-blind
sacral neuromodulation phase, the patients have a neuro-urological re-evaluation, unblinding takes place, and the
neuromodulator is turned ON in all patients. The primary outcome measure is success of sacral neuromodulation,
secondary outcome measures are adverse events, urodynamic parameters, questionnaires, and costs of sacral
neuromodulation.
Discussion: It is of utmost importance to know whether the minimally invasive and completely reversible sacral
neuromodulation would be a valuable treatment option for patients with refractory neurogenic lower urinary tract
dysfunction. If this type of treatment is effective in the neurological population, it would revolutionize the
management of neurogenic lower urinary tract dysfunction.
Trial registration: Trial registration number: www.clinicaltrials.gov; Identifier: NCT02165774.
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Neurogenic lower urinary tract dysfunction (LUTD) is
highly prevalent and affects the lives of millions of people
worldwide. It has a major impact on quality of life and, be-
sides the debilitating manifestations for patients, it also
imposes a substantial economic burden for every health-
care system. Neurogenic LUTD is a challenge because all
available treatment modalities (i.e. conservative, minimally
invasive and surgical therapies) may either fail or be
invasive causing considerable complications and/or
side effects.
Sacral neuromodulation (SNM) [1] has become a well-
established and widely accepted treatment for patients
with refractory LUTD such as non-obstructive chronic
urinary retention, urgency frequency syndrome, and ur-
gency incontinence [2-6] and it has been incorporated
into the guidelines of the European Association of Urology
(EAU) (www.uroweb.org), the International Consultation
on Incontinence (ICI) [7], and the National Institute for
Health and Clinical Excellence (NICE) (www.nice.org.uk).
Originally, SNM was not considered an option for neuro-
genic LUTD but some studies suggested that it is also
effective in neurological patients [3,8]. Considering that
SNM is minimally invasive and completely reversible, it
is of great interest whether this is a valuable treatment
option for patients with neurogenic LUTD. In a recent
systematic review and meta-analysis [9], we found that
there is evidence indicating that SNM may be effective
and safe for the treatment of this group of patients.
However, the number of investigated patients is low
with high between-study heterogeneity and there is a
lack of randomized controlled trials [9].
We therefore designed a prospective, randomized,
placebo-controlled, double-blind multicenter clinical
trial to assess the efficacy and safety of SNM for treating
patients with neurogenic LUTD. The study hypothesis
is that in patients with refractory neurogenic LUTD,
SNM leads to an at least 35% increase in success rate as
compared to placebo (i.e. sham) stimulation within
2 months, i.e. SNM is considerably more effective than
placebo (i.e. sham) stimulation.
Methods and design
Study design
This study is a prospective, randomized, placebo-controlled,
double-blind multicenter trial including 4 SNM refer-
ral centers in Switzerland: Neuro-Urology, Spinal Cord
Injury Center & Research, University of Zürich, Balgrist
University Hospital, Zürich; Department of Urology,
Cantonal Hospital St. Gallen, St. Gallen; Neuro-Urology,
Swiss Paraplegic Center Nottwil, Nottwil; Department of
Urology, University of Bern, Bern.
In case of successful prolonged SNM, the neuromodu-
lator is implanted and patients are randomized using acomputer program considering 3 strata according to the
neuro-urological diagnosis, i.e. a) urgency frequency syn-
drome and/or urgency incontinence, b) chronic urinary
retention, and c) combination of urgency frequency syn-
drome and/or urgency incontinence and chronic urinary
retention. After a 2 months SNM optimization phase
following neuromodulator implantation, the neuromo-
dulator is turned ON or OFF in a 1:1 allocation by an in-
vestigator not involved in the assessment of the clinical
outcome.
The Figure 1 gives an overview of the procedures that
the patients will undergo during the course of the study.
Study population and recruitment
According to the inclusion and exclusion criteria
(Table 1), we will investigate patients with refractory
neurogenic LUTD. The following variables will be con-
sidered: gender, age, neurological disease, duration of
neurological disease, previous treatment, bladder diary
variables, urinalysis, urethro-cystoscopy, bladder washing
cytology, urodynamic investigations, and questionnaires, i.e.
Female Sexual Function Index (FSFI) [10]/International
Index of Erectile Function (IIEF) [11] and Qualiveen [12].
Determination of sample size
We are planning a study of independent cases and con-
trols with 1 control per case. Prior data indicate that the
(spontaneous) success rate among controls is 0.15. If the
true success rate for experimental subjects (SNM ON) is
at least 0.5, we will need to study 27 experimental sub-
jects (SNM ON) and 27 control subjects (SNM OFF) to
be able to reject the null hypothesis that the failure rates
for experimental (SNM ON) and control subjects (SNM
OFF) are equal with probability (power) 0.8. The type I
error probability associated with this test of this null
hypothesis is 0.05. Taking into account potential drop-
outs, we will include 30 patients per group.
Study location and partners
▪ Neuro-Urology, Spinal Cord Injury Center &
Research, University of Zürich, Balgrist University
Hospital, Zürich, Switzerland
▪ Department of Urology, Cantonal Hospital St. Gallen,
St. Gallen, Switzerland
▪ Neuro-Urology, Swiss Paraplegic Center, Nottwil,
Switzerland
▪ Department of Urology, University of Bern,
Switzerland
▪ Department of Clinical Epidemiology and Medical
Technology Assessment, Maastricht University
Medical Center, Maastricht, The Netherlands
▪ Medignition Inc., Research Consultants, Zug,
Switzerland
Refractory neurogenic lower urinary tract dysfunction 
positive negative 
Neuromodulator 
implantation 
Tined lead 
explantation SNM optimization phase (2 months) and randomization 
SNM ON (2 months) SNM OFF (2 months) 
Inclusion criteria fulfilled  study inclusion after written informed consent 
Bilateral tined lead implantation  SNM testing for 3-6 weeks  end of test phase: 
Bladder diary (3 days) 
Urinalysis, urodynamic investigation 
Qualiveen questionnaire 
Female Sexual Function Index / International Index of Erectile Function 
At the end of 2 months double-blind SNM phase: 
Bladder diary (3 days) 
Urinalysis, urodynamic investigation 
Qualiveen questionnaire 
Female Sexual Function Index / International Index of Erectile Function 
Unblinding 
Bladder diary (3 days) 
Urinalysis, urodynamic investigation 
Urethro-cystoscopy, bladder washing cytology 
Qualiveen questionnaire 
Female Sexual Function Index / International Index of Erectile Function 
SNM ON in all patients: study end 
Figure 1 Flowchart of the sacral neuromodulation (SNM) trial. SNM: sacral neuromodulation.
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In case the patients with refractory neurogenic LUTD ful-
fill the study inclusion criteria following neuro-urological
evaluation (bladder diary for at least 3 days, urinalysis,
urodynamic investigation, urethro-cystoscopy and bladderTable 1 Inclusion and exclusion criteria for patients with refra
Inclusion criteria E
▪ Age >18 years ▪
▪ Refractory neurogenic LUTD ▪
▪ Urgency frequency syndrome and/or urgency incontinence refractory to
antimuscarinics (pharmacotherapy for at least 4 weeks with at least 2
antimuscarinics)
▪
▪ Chronic urinary retention refractory to alpha-blocker (pharmacotherapy
with an alpha-blocker for at least 4 weeks)
▪
▪ Combination of urgency frequency syndrome and/or urgency
incontinence refractory to antimuscarinics (pharmacotherapy for at least
4 weeks with at least 2 antimuscarinics) and chronic urinary retention
refractory to alpha-blocker (pharmacotherapy with an alpha-blocker for
at least 4 weeks)
▪
▪ Written informed consent ▪washing cystology, Qualiveen questionnaire [12], FSFI
[10]/IIEF [11], they are included after providing written
informed consent. The Figure 1 gives an overview of the
procedures that the patients will undergo during the
course of the study. After minimally invasive bilateralctory neurogenic lower urinary tract dysfunction (LUTD)
xclusion criteria
Age <18 years
Non-neurogenic LUTD
Botulinum toxin injections into the detrusor and/or urethral sphincter in
the last 6 months
Pregnancy or breast feeding
Individuals especially in need of protection (according to Research with
Human Subjects published by the Swiss Academy of Medical Sciences
(www.samw.ch/en/News/News.html))
No written informed consent
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S4 (stage one), patients undergo prolonged SNM testing
for 3–6 weeks completing a bladder diary to assess the
response to treatment. In accordance with the literature
[5,6], an improvement of at least 50% in the key bladder
diary variables (i.e. number of voids and/or number of
leakages, post void residual) compared to the baseline
values is considered a positive test and an indication
for neuromodulator implantation. At the end of the test
phase, the patients have a neuro-urological re-evaluation
(bladder diary for at least 3 days, urinalysis, urodynamic
investigation, Qualiveen questionnaire [12], FSFI [10]/IIEF
[11]). In case of negative prolonged SNM testing, the tined
leads are explanted. In case of successful prolonged SNM
testing, the neuromodulator is generally implanted in the
upper buttock (rarely in the anterior abdominal wall)
(stage two). After neuromodulator implantation, each
patient has a 2 months phase when the neuromodulator
is turned ON using sub-sensory threshold stimulation
(SNM optimization phase) to optimize the effectiveness
of neuromodulation by determining the most effective
stimulation parameters (choice of stimulation elec-
trodes, intensity of stimulation) for each patient. At the
end of the SNM optimization phase, patients are ran-
domized in a double-blind parallel design to SNM ON
or OFF. During an outpatient visit, neuromodulation
parameters and bladder diary parameters are checked
and the neuromodulator is turned ON or OFF by an in-
vestigator not involved in assessment of the clinical
outcome. Considering that sub-sensory stimulation is
used for SNM, the patients do not feel if the stimula-
tion is ON or OFF. At the end of the 2 months double-
blind SNM phase, the patients have a neuro-urological
re-evaluation (bladder diary for at least 3 days, urinaly-
sis, urodynamic investigation, Qualiveen questionnaire
[12], FSFI [10]/IIEF [11]). During this visit, unblinding
takes place and the neuromodulator is turned ON in all
patients.
Safety
The investigators will inform the patients, the study
monitoring board, and the ethics committee if it be-
comes evident that the disadvantages of participation
may be significantly greater than was foreseen in the re-
search proposal. The study will be suspended pending
further review by the study monitoring board, except
insofar as suspension would jeopardize the patients’
health. The investigators will take care that all patients
are kept informed.
Adverse events will be assessed and categorized accord-
ing to the National Cancer Institute Common Termin-
ology Criteria for Adverse Events (CTCAE) version 4 in
grade 1 to 5 (http://ctep.cancer.gov/protocolDevelopment/
electronic_applications/ctc.htm). All adverse events will befollowed until they have abated, or until a stable situation
has been reached. Depending on the event, follow-up may
require additional tests or medical procedures as indi-
cated, and/or referral to the general physician or a medical
specialist.
In the case of withdrawal of consent to participate
in the study, all possible efforts will be made to con-
vince the patient to continue to have safety follow-up
evaluations.
In the event one of the following situations arises among
treated patients during the conduct of the study, the study
will be temporarily suspended and a comprehensive safety
review conducted evaluating if the study has to be termi-
nated prematurely:
▪ Any death secondary to rapid unexpected progression
of an underlying medical condition.
▪ Severe clinical or neurological deterioration in more
than one subject.
▪ Any other serious adverse event determined by the
study monitoring board to be a reason to suspend the
study.Study outcome measures
Primary: Success of SNM: Defined in accordance with
the literature [5,6] as improvement of at least 50% in the
key bladder diary variables (i.e. number of voids and/or
number of leakages, post void residual) compared to the
baseline values (i.e. patients with urgency frequency syn-
drome and/or urgency incontinence: at least 50% decrease
in number of voids and/or number of leakages; patients
with chronic urinary retention: at least 50% decrease in
post void residual; patients with a combination of urgency
frequency syndrome and/or urgency incontinence and
chronic urinary retention: at least 50% decrease in number
of voids and/or number of leakages, and/or at least 50%
decrease in post void residual).
Secondary: A) Adverse events: Categorization accord-
ing to the National Cancer Institute Common Termin-
ology Criteria for Adverse Events (CTCAE) version 4 in
grade 1 to 5 (http://ctep.cancer.gov/protocolDevelopment/
electronic_applications/ctc.htm).
B) Urodynamic parameters: cystometric capacity (mL),
compliance (mL/cmH2O), detrusor overactivity (if yes:
bladder volume (mL) at detrusor overactivity, maximum
detrusor pressure amplitude (cmH2O), detrusor leak point
pressure (cmH2O)), maximum detrusor pressure (cmH2O),
detrusor pressure at maximum flow rate (cmH2O),
maximum flow rate (mL/s), voided volume (mL), post
void residual (mL), pelvic floor electromyographic
activity (normal/detrusor sphincter dyssynergia).
C) Questionnaires, i.e. Qualiveen and FSFI/IIEF.
D) Costs of SNM.
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Statistics
Interval scaled variates will be summarized with means
and standard deviations (SD) or medians and interquar-
tile ranges where appropriate. Dichotomous variates will
be described as ratios and percentages.
Univariate analysis
T-tests will be used to compare means between groups
and chi-squared tests to compare dichotomous variables.
Multivariate analysis
To adjust for unequal distribution of parameters at base-
line, multivariate regression models, linear models in case
of an interval scaled outcome and logistic regression in
case of a dichotomous outcome will be performed.
Ethics and dissemination
This trial will be performed in accordance with the World
Medical Association Declaration of Helsinki [13], the
guidelines for Good Clinical Practice [14] and the guide-
lines of the Swiss Academy of Medical Sciences [15].
Handling of all personal data will strictly comply with
the federal law of data protection in Switzerland [16].
The trial has been registred at clinicaltrials.gov (www.
clinicaltrials.gov/ct2/show/NCT02165774).
Discussion
First-line treatment for neurogenic LUTD includes anti-
muscarinics and some form of catheterization if neces-
sary, preferably intermittent self-catheterization [17].
However, the treatment effect is often unsatisfactory, so
that other options have to be considered, including ona-
botulinumtoxinA injections into the detrusor [18] or
more invasive procedures such as bladder augmentation
or urinary diversions. Thus, it is of utmost importance
to know whether the minimally invasive and completely
reversible SNM, a well established and widely accepted
therapy for refractory non-neurogenic LUTD, would be
a valuable treatment option for patients with refractory
neurogenic LUTD. In addition, SNM may enable voiding
without intermittent catheterization, the standard tech-
nique for chronic neurogenic urinary retention today. As a
significant number of patients cannot perform this tech-
nique due to the underlying neurological disorder, SNM
may not only prevent major surgery but also life-long
treatment with indwelling catheters, which are related to
significant long-term complications.
Assessing efficacy and safety of SNM for neurogenic
LUTD, it is essential to be aware of the fact that these
patients usually have undergone multiple failed previous
treatments. In the case that SNM is also effective in
the neurological population, this would have majorimplications for daily practice and would completely
revolutionize the management of neurogenic LUTD.
This trial is multidisciplinary and will significantly influ-
ence all involved disciplines, i.e. neuro-urology, urology,
and neurology. Especially in neurology, this project will
increase the awareness of LUTD in neurological disor-
ders and the related effective treatment options includ-
ing SNM.
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